Margaret Meserve

Margaret Meserve

Auto-generated profile, based on publicly available information

Margaret Meserve

Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2025 in Genetics in Medicine
Verified
Journal Article
Closed access
DCDavid Cheerie
David Cheerie
MLMarlen C. Lauffer
Marlen C. Lauffer
LNLogan Newton
Logan Newton
KAKimberly Amburgey
Kimberly Amburgey
DBDanique Beijer
Danique Beijer
GCGregory Costain
Gregory Costain

28 September 2024 in medRxiv
Verified
Preprint
Open access
PDF file
DCDavid Cheerie
David Cheerie
MMMargaret Meserve
Margaret Meserve
DBDanique Beijer
Danique Beijer
CKCharu Kaiwar
Charu Kaiwar
LNLogan Newton
Logan Newton
NCN=1 Collaborative
N=1 Collaborative
Of the around 7,000 known rare diseases worldwide, disease-modifying treatments are available for fewer than 5%, leaving millions of individuals without specialized therapeutic strategies. In recent years, antisense oligonucleotides (ASOs) have shown promise as individualized genetic interventions for rare genetic diseases. However, there is currently no consensus on which disease-causing DNA variants are suitable candidates for this type of genetic therapy. The Patient Identification Working Group of the N=1 Collaborative (N1C), alongside an international group of volunteer assessors, has developed and piloted consensus guidelines for assessing the eligibility of pathogenic variants towards ASO treatments. We herein present the N1C VARIANT ( V ariant A ssessments towa r ds El i gibility for An tisense Oligonucleotide T reatment) guidelines, including the guiding scientific principles and our approach to consensus building. Pathogenic, disease-causing variants can be assessed for the three currently best-established ASO treatment approaches: splice correction, exon skipping, and downregulation of RNA transcripts. A genetic variant is classified as either “eligible”, “likely eligible”, “unlikely eligible”, or “not eligible” in relation to the different approaches, or “unable to assess”. We also review key considerations for assessment for upregulation of transcripts from the wildtype allele, an emerging ASO therapeutic strategy. We provide additional tools and training material to enable clinicians and researchers to use these guidelines for their eligibility assessments. With this initial edition of our N1C VARIANT guidelines, we provide the rare genetic disease community with guidance on how to identify suitable candidates for variant-specific ASO-based therapies and the possibility of integrating such assessments into routine clinical practice.

12 February 2025 in medRxiv
Verified
Preprint
Open access
PDF file
DCDavid Cheerie
David Cheerie
MLMarlen C. Lauffer
Marlen C. Lauffer
LNLogan Newton
Logan Newton
KAKimberly Amburgey
Kimberly Amburgey
DBDanique Beijer
Danique Beijer
GCGregory Costain
Gregory Costain
Purpose: To estimate the proportion of molecular genetic diagnoses in a real-world, phenotypically heterogeneous patient cohort that are amenable to antisense oligonucleotide (ASO) treatment. Methods: We retrospectively applied the N=1 Collaborative’s VARIANT ( V ariant A ssessments towa r ds El i gibility for An tisense Oligonucleotide T reatment) guidelines to all diagnostic variants found by clinical genome-wide sequencing at a single pediatric hospital in 532 patients over a 6-year period. Variants were classified as either “eligible”, “likely eligible”, “unlikely eligible”, or “not eligible” in relation to the different ASO approaches, or “unable to assess”. Results: In total, 25 unique variants across 26 patients (4.9% of 532 patients) were eligible or likely eligible for ASO treatment at a molecular genetic level, via canonical exon skipping (4), splice correction (3), or mRNA knockdown (18). Only eight of these molecular genetic diagnoses were made within a year of symptom onset. After considering disease and delivery related factors, 11 diagnoses were still considered candidates for bespoke ASO development. Conclusion: A meaningful proportion of genetic diagnoses identified by genome-wide sequencing may be amenable to ASO treatment. These results underscore the importance of timely diagnosis, and the proactive identification and accelerated functional testing of genetic variants amenable to ASO treatments.